Back to News
Market Impact: 0.25
Nicox's NCX 470 NDA Gets FDA Acceptance For Glaucoma; PDUFA Date Set For April 2027
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
Nicox said the FDA accepted its NDA for NCX 470 (bimatoprost grenod), an important regulatory step for its ophthalmology drug. The company did not provide the specific PDUFA target action date in the excerpt, but acceptance implies the filing is in process toward an FDA decision under the Prescription Drug User Fee Act framework.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
NICXF0.30
More News
- Cata-Kor Enters Physical Retail with Target Launch, Bringing Its NAD⁺ Longevity Line to Stores Nationwide
- Musk says Terrafab chip factory could outperform rivals despite challenges
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Will Warner Bros. kill Skydance — or will David Ellison kill Warner Bros?
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Cerebras Is About as Big as Nvidia's Data Center Business Was Nearly a Decade Ago. The Similarities Mostly End There.